Efficacy, safety and tolerability of XBD173 in patients with generalized anxiety disorder

Trial Profile

Efficacy, safety and tolerability of XBD173 in patients with generalized anxiety disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2010

At a glance

  • Drugs XBD 173 (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 May 2010 Last checked against ClinicalTrials.gov record.
    • 28 Nov 2007 Status changed from in progress to completed
    • 30 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top